BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 29667330)

  • 1. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study.
    Harada S; Sakai R; Hirano F; Miyasaka N; Harigai M;
    J Rheumatol; 2017 Jul; 44(7):988-995. PubMed ID: 28412701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients.
    Liao TL; Lin CH; Chen HH; Chen YM; Lin CC; Chen DY
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
    Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
    Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
    Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
    Arthritis Care Res (Hoboken); 2015 May; 67(5):731-6. PubMed ID: 25201241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
    Baddley JW; Winthrop KL; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
    Ann Rheum Dis; 2014 Nov; 73(11):1942-8. PubMed ID: 23852763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
    Winthrop KL; Baddley JW; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
    JAMA; 2013 Mar; 309(9):887-95. PubMed ID: 23462785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
    Liao TL; Chen YM; Liu HJ; Chen DY
    BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of opportunistic infection in early rheumatoid arthritis.
    Kim H; Cho SK; Lee J; Bae SC; Sung YK
    Int J Rheum Dis; 2019 Jul; 22(7):1239-1246. PubMed ID: 31090187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.
    Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
    Arthritis Rheum; 2007 Dec; 57(8):1431-8. PubMed ID: 18050184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis.
    Schenfeld J; Iles J; Trivedi M; Accortt NA
    Rheumatol Int; 2017 Jul; 37(7):1075-1082. PubMed ID: 28255642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.
    Sakai R; Cho SK; Nanki T; Koike R; Watanabe K; Yamazaki H; Nagasawa H; Amano K; Tanaka Y; Sumida T; Ihata A; Yasuda S; Nakajima A; Sugihara T; Tamura N; Fujii T; Dobashi H; Miura Y; Miyasaka N; Harigai M;
    Rheumatol Int; 2014 Dec; 34(12):1729-36. PubMed ID: 24852650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.
    Ke WM; Chen LS; Parng IM; Chen WW; On AW
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1590-5. PubMed ID: 24200274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
    Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
    Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
    Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
    Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.